<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077696</url>
  </required_header>
  <id_info>
    <org_study_id>APHP210917</org_study_id>
    <secondary_id>2021-A02460-41</secondary_id>
    <nct_id>NCT05077696</nct_id>
  </id_info>
  <brief_title>Neurofilament Assay for the Diagnosis of ALS</brief_title>
  <acronym>FILSLAN-NF</acronym>
  <official_title>Contribution of the Neurofilament Assay for the Diagnosis of ALS (Amyotrophic Lateral Sclerosis) in Situations of Diagnostic Standoff After Evaluation in an Expert ALS Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the interest of the determination of pNFH and NFL&#xD;
      neurofilaments in serum for the diagnosis of ALS in patients with a diagnostic standoff after&#xD;
      evaluation in an expert ALS center. The hypothesis is that one of these biomarkers, or their&#xD;
      combined analysis, will make it possible to confirm or invalidate the diagnosis of ALS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For this study, which aims to evaluate a test to help in the diagnosis of ALS that could be&#xD;
      integrated into routine practice, it was preferred to use blood tests. Blood sampling is&#xD;
      significantly less invasive than CSF sampling, and more easily generalized, including in&#xD;
      ambulatory conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>contribution of pNFH and NFL neurofilaments assays</measure>
    <time_frame>1 year</time_frame>
    <description>contribution of pNFH and NFL neurofilaments assays in serum for the positive diagnosis of ALS in a selected population of patients with progressive motor neuron disease without definite diagnosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Value of the combined pNFH and NFL neurofilament assay in serum versus the pNFH and NFL assay alone</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the value of the combined pNFH and NFL neurofilament assay in serum versus the pNFH and NFL assay alone for the positive diagnosis of ALS in a selected population of patients with progressive motor neuron disease without a definite diagnosis.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Progressive Motor Neuron Disease Without Definite Diagnosis</condition>
  <arm_group>
    <arm_group_label>Patients with progressive motor neuron disease without definite diagnosis</arm_group_label>
    <description>Patients with progressive motor neuron disease without definite diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Drawing a tube of blood (serum)</intervention_name>
    <description>dosage of neurofilaments and comparison with a final diagnosis one year after sampling.</description>
    <arm_group_label>Patients with progressive motor neuron disease without definite diagnosis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with progressive motor neuron disease without a definite diagnosis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
        Subjects with first and/or second motor neuron disease, evolving clinically and/or&#xD;
        electrically over at least 12 months, not meeting the diagnostic criteria for ALS (revised&#xD;
        El Escorial criteria):&#xD;
&#xD;
          -  Isolated peripheral motor neuron disease (at least one region of the PNM) OR&#xD;
&#xD;
          -  Isolated central motor neuron involvement (at least two areas of the MNC) OR&#xD;
&#xD;
          -  associated involvement of the MNP and MNC but in the presence of an associated&#xD;
             pathology responsible for a persistent diagnostic doubt (double narrow cervical and&#xD;
             lumbar canal, associated evolving cancer evoking a paraneoplastic syndrome without&#xD;
             specific antibody found) Age superior to 18 years Management and follow-up in one of&#xD;
             the French ALS centers Patient able to express his non-opposition Affiliation with&#xD;
             social security or beneficiary of such a plan&#xD;
&#xD;
        Non-inclusion criteria:&#xD;
&#xD;
        Refusal of the patient Person under a legal protection measure (guardianship, curatorship&#xD;
        or safeguard of justice).&#xD;
&#xD;
        Person deprived of liberty by judicial or administrative decision.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria del Mar Amador</last_name>
    <phone>1 42 16 24 72</phone>
    <phone_ext>+33</phone_ext>
    <email>mariadelmar.amador@aphp.fr</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Neurofilaments</keyword>
  <keyword>NFL</keyword>
  <keyword>pNFH</keyword>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>progressive motor neuron disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

